Abstract：
OBJECTIVE: Studies have demonstrated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients. The aim was to review the effect of tofogliflozin on hepatic outcomes in T2DM patients.
METHODS: A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised clinical trials of tofogliflozin by applying predetermined inclusion and exclusion criteria.
RESULTS: A total number of four randomised clinical trials, including 226 subjects, were included in the review. There was a significant decrease in aspartate aminotransferase (AST) and alanine transaminase (ALT) levels in the tofogliflozin group as compared to the control or active comparator groups. Additionally, gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) levels were also significantly decreased in the tofogliflozin group. However, no significant difference was observed in levels of adiponectin.
CONCLUSIONS: Overall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM.
METHODS: A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised clinical trials of tofogliflozin by applying predetermined inclusion and exclusion criteria.
RESULTS: A total number of four randomised clinical trials, including 226 subjects, were included in the review. There was a significant decrease in aspartate aminotransferase (AST) and alanine transaminase (ALT) levels in the tofogliflozin group as compared to the control or active comparator groups. Additionally, gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) levels were also significantly decreased in the tofogliflozin group. However, no significant difference was observed in levels of adiponectin.
CONCLUSIONS: Overall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM.
摘要：
目的：研究表明，在2型糖尿病（T2DM）患者中，非酒精性脂肪性肝病（NAFLD）的患病率较高。目的是回顾托福列净对T2DM患者肝脏预后的影响。
方法：在PubMed，通过应用预定的纳入和排除标准，对托福列净的随机临床试验进行了ScienceDirect和Cochrane中央对照试验注册。
结果：总共四项随机临床试验，包括226个科目，包括在审查中。与对照组或活性比较组相比，tofogliflozin组的天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平显着降低。此外,γ-谷氨酰转移酶（GGT），托福列净组的碱性磷酸酶(ALP)和磁共振成像质子密度脂肪分数(MRI-PDFF)水平也显著降低.然而,脂联素水平无显著差异。
结论：总体而言，在合并肝脏疾病的T2DM患者中观察到肝脏参数水平改善.然而,需要大量临床试验来证明托福列净对T2DM患者肝脏结局的疗效.
方法：在PubMed，通过应用预定的纳入和排除标准，对托福列净的随机临床试验进行了ScienceDirect和Cochrane中央对照试验注册。
结果：总共四项随机临床试验，包括226个科目，包括在审查中。与对照组或活性比较组相比，tofogliflozin组的天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平显着降低。此外,γ-谷氨酰转移酶（GGT），托福列净组的碱性磷酸酶(ALP)和磁共振成像质子密度脂肪分数(MRI-PDFF)水平也显著降低.然而,脂联素水平无显著差异。
结论：总体而言，在合并肝脏疾病的T2DM患者中观察到肝脏参数水平改善.然而,需要大量临床试验来证明托福列净对T2DM患者肝脏结局的疗效.
